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Buruli ulcer is a recognized public health problem in
West Africa. In Benin, from 1989 to 2001, the Centre
Sanitaire et Nutritionnel Gbemoten (CSNG) treated >2,500
Buruli ulcer patients. From March 2000 to February 2001,
field trips were conducted in the Zou and Atlantique
regions. The choice of the 2 regions was based on the dis-
tance from CSNG and on villages with the highest number
of patients treated at CSNG. A total of 66 (44.0%) of 150
former patients treated at CSNG were located in the visited
villages. The recurrence rate of CSNG-treated patients
after a follow-up period of up to 7 years was low (6.1%,
95% confidence interval [CI] 2.0–15.6). We attribute this
low rate to the high quality of Buruli ulcer treatment at an
accessible regional center (CSNG). The World Health
Organization definition of a Buruli ulcer recurrent case
should be revised to include a follow-up period >1 year.
M
ycobacterium ulcerans disease, also called Buruli
ulcer, is a recognized public health problem in many
countries, especially in West Africa, where prevalence has
been increasing in recent years (1,2). Buruli ulcer–endem-
ic foci are regularly associated with stagnant bodies of
water (ponds, backwaters, and swamps). The disease takes
various clinical forms, including ulcers, nodules, plaques,
and edematous indurations. Surgical excision followed by
skin grafting is the recommended treatment (3). Recent
studies, however, suggest that an antimicrobial regimen of
rifampicin (rifampin) plus streptomycin may be effective
against early forms of Buruli ulcer (4). Follow-up data on
the rate of recurrence in hospital-treated Buruli ulcer
patients are rarely reported. In a study designed to assess
the effectiveness of excising preulcerative Buruli lesions in
field situations in Ghana, Amofah et al. found a local
recurrence rate of 16% at the same site within a year of fol-
low-up (5). Two more patients had a recurrence at a differ-
ent site, for a total recurrence rate of 20%. In villages in
Ghana, Teelken et al. compiled a group of 78 patients who
had been treated in 2 different hospitals: 35% were not
healed when followed up 3 years later. For 1 hospital, the
rate of those not healed was 18%, and in the other, 47%. In
their study, however, investigators were not able to differ-
entiate between ulcers that had never healed and those that
healed and then recurred (6).
Our village follow-up was organized and carried out by
the Centre Sanitaire et Nutritionnel Gbemoten (CSNG), a
rural health center in southern Benin that began surgically
treating patients in 1989 (7). This study reports the recur-
rence rate of CSNG-treated patients after up to 7 years of
follow-up.
CSNG, in the district of Zagnanado, is one of several
reference centers for the treatment of Buruli ulcer in
Benin. Situated in the Zou region, 1 of 4 Buruli
ulcer–endemic regions of southern Benin, this center
receives Buruli ulcer patients from Benin and neighboring
countries. From 1989 to 2001, CSNG treated 2,564 Buruli
ulcer patients (2): 1,801 were from Zou, 170 were from
Atlantique, and 515 were from other regions of southern
Benin. The origin of 78 patients was not recorded. From
March 2000 to February 2001, field trips in villages of the
Atlantique and Zou regions were organized to collect data
on rates of recurrence of disease and inform the population
of the Buruli ulcer public health problem. CNSG could not
collect data before 2000 because of a lack of transporta-
tion. In a previous study, the origin and number of patients
coming to CNSG for treatment were described (2). We
showed that most Buruli ulcer patients admitted to CSNG
from 1997 to 2001 were from Zou, and <10% were from
the adjacent Atlantique region (2). For villagers living at a
distance from CSNG, transportation and treatment costs
represent a considerable concern, but the greatest expendi-
ture for patients is the cost of living at CSNG, especially
the cost of food (8). 
Methods
From March 2000 to February 2001, 22 field trips were
conducted in Zou and Atlantique. Eleven field trips were
required to inform the local authorities about the objectives
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time and date of the follow-up visit 15 days later.
Detecting Buruli ulcer patients required 11 additional field
trips.
Villages that were included in the study had to be in a
region close to CSNG (Zou), where villagers were aware
of the availability of a Buruli ulcer treatment center, or in
a region far from CSNG (Atlantique), where distance to
the center was a substantial problem. In each region, a list
of patients from each region was compiled, and the dis-
tricts and villages with the highest number of patients
treated at CSNG were selected. 
The field team included a staff physician of the CSNG,
a microbiologist, and a driver. Publicity campaigns on
Buruli ulcer were presented by CSNG in some villages in
these regions. Before field trips, we compiled a list of
Buruli ulcer patients from villages where publicity cam-
paigns were organized. These patients were treated at
CSNG at some point from 1989 to 2001. They were exam-
ined and interviewed with the cooperation, when neces-
sary, of other persons, such as former patients treated at
CSNG, teachers, parents, or for children, someone desig-
nated as representative of specific patients. These key per-
sons helped us locate patients on our lists and sometimes
find new patients and patients treated by traditional meth-
ods. All adolescent and adult participants were personally
interviewed. For children, a competent adult who knew the
study patient well enough to supply the requested informa-
tion was interviewed. All patients, or parents of children
included in the study, provided oral consent. Photographs
were taken of some patients.
Posttreatment histories were taken in the language of
each patient, either directly by the interviewer or through
an interpreter, when necessary. Recurrences of Buruli ulcer
symptoms were noted, specifically with respect to types
and sites of new lesions and time between hospital dis-
charge and follow-up. All patients with active Buruli ulcer
were referred to CSNG.
Clinical diagnosis of 49 cases was confirmed by labo-
ratory tests according to World Health Organization
(WHO) guidelines (9). The remaining 17 cases were diag-
nosed clinically; all were typical Buruli ulcer and did not
present reasonable differential diagnostic problems.
Results
Table 1 shows the total number of villages (173) in the
3 Buruli ulcer–endemic districts (28 in Ouinhi, 74 in
Zogbodomey, and 71 in Zè). From 1989 to 2001, a total of
70 villages (40%) were Buruli ulcer–endemic in the Zou
and Atlantique regions. Two districts from the Zou region,
Ouinhi and Zogbodomey, had 21 and 24 Buruli
ulcer–endemic villages, respectively, and in the Atlantique
region, 1 district (Zè) had 25 Buruli ulcer–endemic vil-
lages. Of 70 Buruli ulcer–endemic villages, 24 (34.3%)
could be visited from March 2000 to February 2001, 13
(28.9%) in Zou and 11 (44.0%) in Atlantique.
A total of 707 patients treated at CSNG originated in
these districts: 419 from Ouinhi, 170 from Zogbodomey,
and 118 from Zè. A total of 150 patients came from visit-
ed villages: 74 from Ouinhi, 39 from Zogbodomey, and 37
from Zè. Atotal of 66 (44.0%) of 150 Buruli ulcer patients
formerly treated at CSNG were located, 41 (36.3 %) from
Zou and 25 (67.6%) from Atlantique. The difference
between the percentage of patients retrieved in Zou and
Atlantique is significant (p < 0.001). We incidentally found
11 patients treated or under treatment by traditional healers
and 28 new patients (data not shown).
The follow-up period (time between discharge and the
follow-up visit) is indicated in Table 2. A total of 45
patients (73.8%) had at least 12 months of follow-up time
(median 34 months), 12 patients (19.7%) had 6–11 months
of follow-up time (median 9 months), and 4 patients
(6.6%) had 2–5 months of follow-up time (median 4
months). The shortest period between hospital discharge
and follow-up visit was 2 months, and the longest period
was 7 years. For 5 patients, the exact date of discharge
from the hospital was not recorded. All 5 patients had bone
lesions, had been hospitalized several times, and had been
discharged >1 year before the visit.
Of the 66 patients treated at CSNG, 4 (6.1%, 95% con-
fidence interval [CI] 2.0–15.6) had a new Buruli lesion.
One patient (4.0%) of 25 came from Atlantique and 3
(7.3%) of 41 from Zou (Table 3). The difference was not
significant.
The location, type, and size of previous and new lesions
are indicated in Table 4. Three patients had a cutaneous
lesion at the previous site, and 1 had a large edematous
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(right tibia). The follow-up times of these 4 recurrent cases
ranged from 12 to 30 months. At CSNG, 57 patients (3.4%,
95% CI 2.6–4.4) of the 1,687 admitted from 1997 to 2001
returned spontaneously to the center with a recurrent lesion
(2). The follow-up times of these recurrent cases ranged
from 1 to 68 months. Of the 4 recurrent cases, 2 developed
within a year, decreasing the recurrence rate within 1 year
to 3.0% (95% CI 0.5–11.5). The 2 other recurrent lesions
had developed by follow-up visits at 17 and 30 months.
Of the 66 patients treated at CSNG and followed-up in
the villages, 10 had received antimycobacterial drugs
(streptomycin and rifampin) 1 or 2 days before surgical
excision and a few days after surgery; 2 of them had recur-
rent cases.
Discussion
The importance of follow-up of Buruli ulcer patients is
accepted but little studied. Recurrences of Buruli ulcer are
not exceptional (10). Early follow-up is important to rap-
idly detect recurrent cases and refer patients to treatment.
Delays in seeking medical advice can lead to severe com-
plications, including dissemination of disease, especially
the development of bone lesions (2,11).
Scheduled programs for repeated follow-up visits of all
treated patients would be ideal but are rarely successful in
most disease-endemic areas. In our study, only 66 (9.3%) of
707 patients from Ouinhi, Zogbodomey, and Zè treated at
CSNG could be followed up. Not all Buruli ulcer–endemic
villages could be visited, for financial and logistic reasons.
In the 24 visited villages, 44% of former patients were
located. If patients were not at home each time we visited
them, friends or relatives were able locate them. The
patients we could not find were those who lived outside the
villages in dwellings that were distant and difficult to reach.
Buruli ulcer is well known to the villagers in disease-
endemic areas. In Atlantique and Zou, the field officer, a
resident villager, listed all Buruli ulcer patients in his vil-
lage and guided the team to each patient’s house. These
guides (often teachers) offered their help for this sponta-
neously, without compensation, and were motivated by
their concern for this health problem. All patients treated
at CSNG (recurrent case or not) welcomed the survey
team with enthusiasm. However, we cannot exclude the
possibility that some patients were not located, especial-
ly patients who had been treated by traditional practi-
tioners.
More patients were located in Atlantique (67.7%) than
in Zou (36.3%). This finding may be partially due to the
fact that most cases in patients from Atlantique were diag-
nosed from 1999 to 2001, while patients from Zou were
treated before 1989. Therefore, locating recent patients
from Atlantique was easier than finding those from Zou
who were treated >10 years ago. In addition, all patients
from Atlantique came from 1 district and were concentrat-
ed in geographically restricted areas that were easy to sur-
vey. Patients from Zou were more geographically
dispersed. Access to some villages and to some houses out-
side the villages was in general more difficult in Zou dis-
tricts than in the Atlantique district. 
The Buruli ulcer recurrence rate in CSNG-treated
patients was low (6.1%) in comparison with those usually
reported. Lunn found recurrence rates from <20% to >50%
(12). According to WHO, these rates vary from 16% for
patients whose conditions are diagnosed early to 28% for
patients who seek treatment late (13). In the 2 field studies
in Ghana, recurrence rates were 16%–47% (5,6). Even
though some rates reported from Ghana are somewhat
higher than our highest rate, we do not consider the differ-
ences meaningful. 
Recurrence rates are directly proportional to the length
of follow-up. Muelder and Nourou followed up 28 patients
from Sagon (Benin) for up to 42 months and found that the
longer the follow-up periods, the higher the accumulative
recurrence rate (14). In our study with a follow-up period
of up to 7 years, most patients treated at CSNG were in
good health.
Two of our recurrent cases did not fit into the defini-
tion of recurrences established by WHO, namely, that the
recurrence should appear within 1 year of completing
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patients came to CSNG with a recurrence >1 year after
discharge from the center, most of them with bone lesions.
Among the 4 patients who had a recurrence of the disease,
a new lesion developed in l patient at a site distant from
the initial lesion. This patient had a bone lesion at the time
of his first disease episode. Patients with bone lesions are
prone to have disseminated lesions at multiple sites (2,11)
and to have recurrences >1 year after discharge from the
hospital (11). Detecting such disseminated lesions should
also imply a follow-up period longer than 1 year.
According to our results and those of previous studies, the
WHO definition of recurrence should be revised to
include a follow-up period longer than 1 year (“delayed
recurrence”).
As for other disease such as tuberculosis (15) or urinary
tract infections (16), distinguishing recurrence or relapse
(endogenous recurrent infection) from reinfection (exoge-
nous recurrent infection) is important in Buruli ulcer. This
distinction cannot yet be rigorously made for Buruli ulcer,
but considering a second lesion that appears next to or
within the first lesion as relapse seems reasonable. In the
case of bone lesions, however, we propose the term relapse
can also be applied even if the second lesion is situated far
from the first lesion (11). Recurrence at a different site
may result from hematogenous or lymphatic spread of the
etiologic agent from earlier M. ulcerans disease at a differ-
ent site. In this case, bone is almost always associated with
new lesions; however, they may result from reinfections.
The development of fingerprinting molecular biology
tools, for example, restriction fragment length polymor-
phism (17) and mycobacterial interspersed repetitive
unit–variable-number tandem repeat (18), seems promis-
ing for the resolution of this problem.
Reinfection seems to be infrequent. Gooding et al.
demonstrated that when Buruli ulcer does not develop in
persons who have been exposed to M. ulcerans, they have
probably developed an immune response to M. ulcerans
(19). This finding confirms the earlier hypothesis that dis-
ease develops in only a portion of exposed persons in
Buruli ulcer–endemic areas (20). In addition, small, self-
healing minor ulcers may go undetected or dismissed by
the patient (21).
Treatments other than surgery also led to recurrences.
Meyers et al. (22) reported 2 recurrent cases among 6
Buruli ulcer patients after heat treatment. The follow-up
periods of the 6 patients ranged from 3 to 22 months. In
both patients, the recurrence was at a site distant from the
heat-treated lesion, and no evidence showed that the initial
lesion had reactivated or that the new lesions represented
extension of the heat-treated ulcers. In fact, 1 of the 2
patients had 2 previous recurrences, and the other returned
19 months after hospital discharge with new, large Buruli
lesions on ankles and lower legs. The authors suggested a
probable reinfection from the environment.
Some antimycobaterial drugs are effective against M.
ulcerans in vitro (23,24) and in vivo in animals (25,26),
but the effect of antibacterial treatment in humans remains
obscure (27,28). Recently, Grosset (4) demonstrated that
early forms of Buruli ulcer may be treated by a combina-
tion of streptomycin and rifampicin. In our study, the
number of patients who received antimycobacterial treat-
ment was small (10), and the duration of treatment was
too short (1–2 weeks) to expect any noticeable effect.
Moreover, 2 of our recurrent case-patients had received
antimycobacterial treatment. Therefore antimycobacterial
use would not be expected to explain, even in part, the low
rates of recurrence observed in the present study.
Antibiotherapy is considered an adjuvant or complemen-
tary treatment to surgery. Effective bactericidal drugs for
humans remain a research priority and may play a role in
reducing recurrences.
Few health professionals are knowledgeable about
Buruli ulcer or have worked in Buruli ulcer–endemic
areas. Buruli ulcer does not yet appear in health statistics,
and few physicians or surgeons are trained to treat this dis-
ease. Recurrences of Buruli ulcer could likely be reduced
by improving training of doctors in correct excision proce-
dures (6) and by following up patients regularly. 
Not all villages of the Buruli ulcer–endemic districts
chosen in the present study were known to be Buruli
ulcer–endemic. As shown in Table 1, Buruli ulcer was
endemic in 70 of 173 villages (40.5%). Although not the
object of the present study, Buruli ulcer–nonendemic vil-
lages should be studied further to determine their true level
of Buruli ulcer endemicity. Further research should also
compare Buruli ulcer–endemic and Buruli ulcer–nonen-
demic villages from the same district to determine which
factors may play a role in the prevalence of Buruli ulcer
(29).
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after surgery at CSNG after a follow-up period ranging
from 2 months to 7 years is low. Creating regional centers
that allow patients easy access to treatment with short trav-
el distances and low treatment costs, coupled with educa-
tional sessions, could help other centers attract and treat
most Buruli ulcer patients in their region. This proximity
would render the follow-up of patients easier and be a
source of new information on the disease for the popula-
tion. This process would lessen the stigma of Buruli ulcer
by considering it a disease and limiting the number of
Buruli ulcer patients who attend traditional healers.
Research to develop an effective antimycobacterial treat-
ment remains a priority, and progress in this area may alle-
viate the problem of recurrences. New molecular tools
may help differentiate recurrence and reinfection and clar-
ify the definition of a recurrent case.
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